Welcome to our dedicated page for ENSIGN GROUP SEC filings (Ticker: ENSG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ensign Group, Inc. (ENSG) filings document its public-company reporting as a Delaware healthcare services company with common stock listed on the Nasdaq Global Select Market. Its disclosures cover skilled nursing and senior living operations, therapy and rehabilitative services, healthcare real estate, and the Standard Bearer real estate segment.
Ensign’s 8-K reports disclose quarterly and annual operating results and Regulation G non-GAAP measures, including adjusted net income, adjusted earnings per share, EBITDA, adjusted EBITDA, adjusted EBITDAR, adjusted EBT, and Funds from Operations for its real estate segment. Proxy materials cover shareholder voting, board governance, executive compensation, equity awards, capital-structure matters, and other governance disclosures.
The Ensign Group, Inc. (ENSG) reported that its Board of Directors approved amended and restated bylaws effective August 20, 2026. The revisions align the bylaws with developments in Delaware law and clarify Board and meeting chair powers to regulate conduct at stockholder meetings.
The bylaws update procedural mechanics and disclosure requirements for stockholder director nominations and other business proposals, expanding the scope of information required about proposing stockholders, nominees and related persons. They also change the timing window for advance notice to generally 90 to 120 days before the anniversary of the prior annual meeting, with specific rules if a meeting is held more than 60 days after that anniversary.
Director candidates are now required to be available for interviews by Board members regarding their candidacy and qualifications. For the 2027 annual meeting, written notice of stockholder nominations or other business (outside Rule 14a-8) must be received between January 13, 2027 and February 12, 2027, while previously announced Rule 14a-8 and Rule 14a-19 deadlines remain unchanged.
The Ensign Group, Inc. (ENSG) entered into a Fourth Amended and Restated Credit Agreement on August 19, 2026, increasing its revolving credit facility by $200 million to an aggregate principal amount of $800 million and extending the maturity to August 19, 2031. Truist Bank acts as administrative agent for a lending syndicate that includes several major U.S. banks. Borrowings bear interest, at Ensign’s option, at either a base rate plus 0.25%–1.00% per year or Term SOFR plus 1.25%–2.00% per year, in each case tied to the ratio of Consolidated Total Net Debt to Consolidated EBITDA. Ensign will also pay a 0.175%–0.30% annual commitment fee on unused commitments and a drawn commitment fee of 1.25%–2.00% per year. Obligations are joint and several with Standard Bearer Healthcare REIT, Inc., guaranteed by certain domestic subsidiaries, and secured by liens on certain assets, with customary events of default.
ENSIGN GROUP, INC President and COO Burton Spencer reported a bona fide gift transfer of 2,500 shares of common stock on August 11, 2026. The transfer was effected pursuant to a Rule 10b5-1 trading plan adopted on February 9, 2026. After the gift, he directly holds 65,970 shares of common stock.
Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of common stock of The Ensign Group, Inc. on an amended Schedule 13G. The group reports beneficial ownership of 2,873,200 shares of common stock, representing 4.91% of the class.
Vanguard Portfolio Management has sole voting power over 6,641 shares and sole dispositive power over 2,873,200 shares, with no shared voting or dispositive power. The holdings include securities held by Vanguard funds and other managed accounts over which Vanguard Portfolio Management or its specified affiliates exercise dispositive and/or voting power, and no other individual person’s interest exceeds 5% of the class.
Ann Scott Blouin, a director of Ensign Group, Inc., reported sales of a total of 375 shares of Common Stock on July 27, 2026, in two transactions of 175 shares at $181.88 and 200 shares at $185.00 per share. These trades were effected under a Rule 10b5-1 trading plan adopted on March 12, 2026.
BlackRock, Inc. filed an amended Schedule 13G/A reporting its beneficial ownership of common stock of Ensign Group Inc.. BlackRock reports beneficial ownership of 5,296,929 Ensign Group common shares, representing 9.1% of the class.
BlackRock has sole voting power over 5,160,565 shares and sole dispositive power over 5,296,929 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends and sale proceeds, but no single person has more than five percent of Ensign’s outstanding common shares.
An equity holder of Ensign Group (ENSG) filed a Form 144 indicating an intent to sell 375 shares of common stock on NASDAQ through Fidelity Brokerage Services LLC, with an aggregate value of $68,829.00 as of a proposed sale date of 07/27/2026. The shares relate to prior restricted stock vesting awards, including 210 shares vested on 07/15/2021 and 165 shares vested on 10/15/2021 as compensation from the issuer.
The Ensign Group, Inc. reported strong second-quarter 2026 results, with consolidated revenue of $1,440,481 (in thousands), GAAP diluted earnings per share of $1.68 and adjusted EPS of $1.92, all showing double‑digit year‑over‑year growth. GAAP net income was $99.7 million, while adjusted net income reached $114.3 million. Adjusted EBITDA was $181,149 (in thousands), and Standard Bearer segment FFO was $24.7 million, each increasing versus the prior-year quarter.
Operationally, Same Facility skilled services revenue rose 6.6% and Transitioning Facility revenue 6.1%, with total skilled services revenue up 17.6%. Same Facility and Transitioning Facility occupancy were 84.1% and 84.7%, respectively, and clinical metrics from CMS showed materially better outcomes than industry and national averages.
On the strength of these results, Ensign raised its 2026 guidance for diluted EPS to $7.75 to $7.85 and revenue to $5.87 billion to $5.92 billion, above prior ranges. The company ended June 30, 2026 with $262.3 million of cash, $591.6 million of available credit capacity, 398 healthcare operations, and paid a quarterly dividend of $0.065 per share.
Ensign Group, Inc. director John O. Agwunobi sold 392 shares of common stock on July 20, 2026 at $171.06 per share in an open market or private transaction. The sale was executed under a Rule 10b5-1 trading plan adopted on July 31, 2025. After this trade, he directly owns 9,503.149 shares.